Background: Mesenchymal stem cells (MSCs) had received much attention in recent years owing to their capacity to differentiate intaao many other cell types. Currently a lot of studies found that MSCs could secrete cytokines and chemokines which affect the growth of tumor cells. Adipose derived mesenchymal stem cells (ADSCs) could differentiate into a variety of different cells as well which were available easier. They could affect the growth of tumor cells, but the mechanism was not clear. We were trying to investigate their effect on bladder cancer cells growth to illustrate the possible mechanisms. Methods: Transwell chamber co-culture was used to observe the effect of ADSCs on bladder cancer cell line T24 and EJ growth. T24 and EJ cells were cultured with condition medium of ADSCs and then recorded tumor cell activity by MTS assay. We used AnnexinV-PI double staining for tumor cell apoptosis, colony formation assay for tumor cell proliferation, wound healing for tumor cell migration, western blot for 5 detecting tumor cell associated protein expressing and molecular signaling pathways. Results: The cell counting and colony formation assay showed ADSCs inhibited the proliferation of EJ and T24 cells. Cell viability assessment revealed that the secretions, in the form of conditioned medium, were able to decrease cancer cell viability. Wound-healing assay suggested ADSCs suppressed migration of T24 and EJ cells. Moreover, the results of the flow cytometry indicated that ADSCs were capable of inducing apoptosis of T24 cells and inducing S phase cell cycle arrest. Western blot revealed ADSCs increased the expression of cleaved Caspase-3 and cleaved PARP, indicating that ADSCs induced apoptosis in a caspase-dependent way. PTEN/PI3K/Akt pathway and Bcl-2 family proteins were involved in the mechanism of this reaction.
Conclusions:
For the first time, we have provided the evidence to prove that ADSCs could obviously inhibit the proliferation of bladder cancer cells through apoptosis. The antiproliferative effect of ADSCs on bladder cancer cells appears to be mediated by the secretion of soluble factors which are involved in the PTEN/PI3K/Akt signaling pathway. Since ADSCs can be easily obtained as a stem cell source without ethical concerns and can be amplified quickly, ADSCs may provide a promising and practicable manner for bladder cancer therapy. However, further in vivo studies are needed to provide a more comprehensive insight into its antitumor effect. Background: To investigate the status of miR-126 and its targeting Spred1 under the stimulation of glucose and Age-BSA and to explore the effect of icariside II (ICA II) on the diabetic endothelial dysfunction of human cavernous endothelial cell (HCECs) by using the miR-126 pathway. Methods: Purified HCECs were divided into three groups: normal group + BSA (NC group), Glucose + Age − BSA group (DM group), ICA II treatment group (DM + ICA II group). Western blot to detect the expression of eNOS, RAGE protein expression so as to make sure the success of model construction; immunofluorescence assay to study the proliferation of (HCECs); real time PCR to detect the expression of miR-126 and Spred1; western blot to detect the expression of the Spred1/c-Raf/MEK1/2/Erk1/2. Tube Formation Assay and Scratch assay were performed to detect the angiogenesis of HCECs under the diabetic-like environment.
Results: Under the model, the expression of eNOS in DM group significantly reduced compared with that of NC group and the expression of RAGE in DM group is significantly increased compared with that of NC group (P<0.05), but the DM + ICA II group showed higher eNOS expression and lower RAGE expression compared with those in the DM group. The Ki67 expression in DM group is lowered than that in NC group; whereas the Ki67 expression in DM + ICA II group is higher when compared with that in DM group. The expression of miR-126 in DM group is significantly reduced compared with that of NC group but the DM + ICA II group showed higher miR-126 expression compared with that in the DM group. Western blot results showed Spred1 expression increased under the diabetic condition and its downstream target genes c-Raf/ MEK1/2/Erk1/2 expression decreased obviously, but ICA II adding into the DM group could reverse these results effectively. Tube Formation Assay and Scratch assay also showed ICA II could promote the tube formation and cell proliferation in impairment of endothelial dysfunction of DM group. Conclusions: Under the simulation of Age-BSA and glucose, HCECs occurred the endothelial dysfunction and the angiogenesis were repressed; ICA II could restore the HCECs functions by miR-126/Spred1/c-Raf/MEK1/2/ Erk1/2 pathway. ICA II may be a promising therapeutic compound to treat endothelial dysfunction in the future. -155, miR-543, miR-31, miR-429, miR-200b were further verified by real-time PCR in a diabetic-like condition. Expressions levels of miRNAs, eNOS and the receptor for advanced glycation end products (RAGE) were performed by Real-time PCR; Protein expression levels of eNOS and RAGE were analyzed by western blot; nitric oxide (NO) content was detected by DAF-FM DA probe and NaNO 2 standard curve methods. Results: The expression of miR-155 in DM group is significantly higher than that that in the normal control (NC) group, whereas this phenomenon was effectively reversed by ICA II treatment. Furthermore, the miR-155 targeting gene eNOS and its consequent NO product were significantly reduced in DM group, while these changes were also recovered after ICA II treatment.
In this study, we demonstrated that ICA II could promotes eNOS mRNA and protein levels by suppressing miR-155 in HCECs exposed to a diabetic-like environment.
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